We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Draft Guidance Eases Endpoint For Chronic Hepatitis C Trials
Draft Guidance Eases Endpoint For Chronic Hepatitis C Trials
October 24, 2013
Sponsors of direct-acting antiviral (DAA) drugs for the treatment of chronic hepatitis C got some relief in the form of a relaxed endpoint for use in late-stage studies.